Leucine-rich alpha-2 glycoprotein as a superior biomarker to C-reactive protein for detecting small bowel lesions in Crohn’s disease

Table 2 Characteristics of the patients in each group, n (%)

Variables	EH group (n = 61)	Ileal group (n = 43)	Colonic group (n = 16)	Ileocolonic group (n = 13)	P value
Sex, male	46 (75.4)	34 (79.1)	12 (75.0)	11 (84.6)	0.886
Age, median years (IQR)	35 (25.5-47)	38 (29-50.5)	42.5 (25.5-48.3)	36 (21.5-51)	0.870
BMI, median years (IQR)	20.9 (19.4-24.4)	21.2 (19.3-24.6)	20.8 (18.8-23.8)	20.2 (18.3-23.1)	0.760
Location					N/A
L1: Ileal	20 (35.0)	23 (56.1)	0 (0)	0	-
L2: Colonic	6 (9.8)	0 (0)	4 (25.0)	0	-
L3: Ileocolonic	35 (57.4)	20 (32.8)	12 (75.0)	13 (100)	-
Behavior					0.0002
B1: Inflammatory	35 (57.4)	4 (6.6)	7 (43.8)	5 (38.5)	-
B2: Stricturing	15 (24.6)	28 (45.9)	6 (37.5)	5 (38.5)	-
B3: Penetrating	11 (18.0)	11 (18.0)	3 (18.8)	3 (23.1)	-
Previous intestinal resection	9 (14.8)	20 (32.8)	7 (43.8)	6 (46.2)	0.002
Concomitant treatment
5-Aminosalicylic acid	35 (57.4)	24 (39.3)	6 (37.5)	5 (38.5)	0.356
Steroids	0 (0)	1 (16.4)	0 (0)	0 (0)	0.541
Immunomodulator	17 (27.9)	13 (21.3)	3 (18.8)	1 (7.7)	0.357
Biologics	51 (83.6)	26 (42.6)	11 (68.8)	6 (46.2)	0.012
Anti-TNF alpha	29 (47.5)	6 (9.8)	5 (31.3)	4 (30.8)	0.005
Anti-integrin	1 (16.4)	2 (3.3)	1 (6.3)	0 (0)	0.622
Anti-interleukin; 12/23 p40	18 (29.5)	16 (26.2)	5 (31.3)	1 (7.7))	0.245
Anti-interleukin; 23 p19	3 (4.9)	2 (3.3)	0 (0)	1 (7.7)	0.780
JAK inhibitor	0 (0)	1 (1.6)	0 (0)	0 (0)	0.655

IQR: Interquartile range; BMI: Body mass index; TNF: Tumor necrosis factor; JAK: Janus kinase; N/A: Not applicable.